Thermo Fisher

Thermo Fisher announced it will expand its cell and gene therapy manufacturing capacity at its Lexington, Massachusetts facility, adding roughly 100,000 square feet dedicated to viral vector production. This follows similar expansions at its sites in Bloomington and Greenville as demand for AAV and lentiviral vector manufacturing ramps with the wave of gene therapy IND filings.

Thermo Fisher's Life Sciences Solutions segment is going to be the story in the back half of 2025 as biopharma restocking kicks in. Companies have been drawing down reagent and consumable inventories for two years and that cycle is close to an end. The Gibco cell culture and Invitrogen lines alone have enormous pricing power when demand snaps back.

It's interesting that Thermo Fisher has essentially built a closed ecosystem across the drug development workflow — from early discovery reagents through Gibco and Applied Biosystems, into clinical manufacturing via Patheon, and then clinical trials through PPD. The strategy is coherent but it also means when biopharma spending slows, every segment gets hit simultaneously rather than having any natural offset.

The pharma services segment, which includes Patheon contract manufacturing, is facing serious pricing pressure as big pharma looks to cut outsourcing costs. PPD clinical research services is also running into a slower clinical trial environment. Neither of these was a concern two years ago but both are real headwinds now.

China revenue is a real problem that keeps getting minimized. Thermo Fisher generates roughly 8-9% of total revenue from China and the combination of domestic instrument substitution programs, regulatory friction, and the general slowdown in Chinese biopharma funding is not a short-term issue. Local competitors like BGI and domestic mass spec makers are getting meaningful government support.

The Orbitrap Astral launch is being massively underappreciated. This instrument offers single-cell proteomics resolution that was basically impossible two years ago and it's already showing up in Nature publications from top labs. Instruments like this create 10-15 year reagent and consumable pull-through revenue streams.

Does anyone have a good read on how much of Thermo Fisher's analytical instruments revenue — things like the Orbitrap mass spectrometers and the Vanquish HPLC systems — is tied to academic and government research budgets versus industrial and pharma QC? Trying to understand NIH budget cut exposure here.

Thermo Fisher's capital allocation has been interesting to watch — they did the PPD acquisition for 17 billion in 2021, then paused M&A significantly as rates rose, and are now sitting on substantial free cash flow with a balance sheet that's deleveraged back toward their target range. The question is whether the next big deal is another services business or a return to instruments and reagents.